Researchers developed promising α-synuclein PET tracers that can visualize protein aggregates in living patients, enabling earlier diagnosis and treatment monitoring. Tracers like [18F]C05-05 and [18F]ACI-12589 showed significant results in distinguishing synucleinopathies from healthy controls.
A study of nearly 11,000 individuals found that men with panic disorder are more vulnerable to developing problematic drinking behaviors than women, potentially due to self-medication. The research highlights the need for sex-specific assessment and intervention strategies in treating comorbid conditions
Researchers using multi-omics tools analyze blood-derived immune cells to chart disease heterogeneity in unprecedented detail. This approach enables exploration of pre-existing immune states shaped by past infections, environmental exposures, and genetic predisposition.
Common prescription medications can disrupt sterol biosynthesis, potentially causing developmental disorders. The editorial highlights the need for mandatory sterol biosynthesis screening in clinical practice.
A single dose of a psychedelic compound can enhance cognitive flexibility for weeks after administration, according to a groundbreaking study. Mice treated with the compound showed improved performance in reversal learning tasks compared to control groups when tested weeks later.
A new study published in Brain Medicine found that administering Osanetant shortly after a traumatic event significantly dampens fear expression in female mice. This suggests that targeting fear memory at its roots may be an effective intervention to reduce PTSD-like behaviors.
Dr. Romina Mizrahi's PET-based neuroimaging sheds light on brain workings, integrating genetics, environment and imaging to understand psychiatric illness as a complex biological puzzle. She advocates for precision psychiatry paradigm with customized treatments based on molecular profiles, and calls for diversity in academic leadership.
Dr. Consuelo Walss-Bass shares her groundbreaking research on schizophrenia, emphasizing the importance of considering both genetic predisposition and environmental factors. She also discusses her work with induced pluripotent stem cells to develop personalized psychiatry and reduce stigma around mental health.
A review article reveals CD2AP's crucial role in amyloid metabolism, tau pathology, synaptic function, and neuroinflammation in Alzheimer's disease. CD2AP deficiency accelerates plaque formation, while its loss in neurons leads to reduced spine density and impaired synaptic plasticity.
A new study reveals that maternal immune activation can alter hippocampal neuron excitability in newborn rats, with implications for neurodevelopmental disorders. Prenatal inflammation has been linked to conditions like autism, schizophrenia, and depression, and may underlie their increased risk.
Dr. Melissa Perreault's research combines cutting-edge science with Indigenous knowledge, pioneering sex-specific biomarkers, neuroethics, and psychedelics research in neuropsychiatry. Her work aims to promote inclusive methodologies that consider diverse worldviews and cultural understandings of health.
Dr. Nicholas Fabiano's research reveals exercise reduces suicide attempts but shows no connection to thoughts of suicide or deaths by suicide. His work proposes a paradigm shift in mental health treatment, suggesting exercise as a first-line treatment for depression.
Dr. Guy Rouleau, a renowned geneticist and neurologist, has founded the world's first academic institution committed to open science principles. The Neuro institute aims to transform how brain disease research is conducted worldwide by promoting data sharing and collaboration.
Researchers have discovered alarming levels of microplastics in human brain tissue, with concentrations 3-5 times higher in individuals with dementia diagnoses. The study highlights the need for large-scale human studies to determine dose-response relationships between microplastic exposure and chronic health outcomes.
Targeted alpha therapy shows promise in treating resistant NETs, offering a precision tool for patients exhausted by conventional treatments. Early preclinical trials have delayed tumour growth with minimal toxicity, while clinical studies have reported high disease control rates.
Researchers have discovered that commonly prescribed medications can disrupt sterol biosynthesis in developing brains, potentially affecting neural development and function. The study highlights the need for reevaluating medication safety during pregnancy and early childhood.
Researchers outline critical safeguards needed to balance public health benefits with Indigenous data sovereignty rights. The study highlights the risks of DNA persistence in wastewater samples, which can reveal sensitive information about community health.
A comprehensive review published in Brain Medicine maps out the extensive influence of reproductive hormones on neurological health and disease. The study examines how sex hormones affect a broad spectrum of neurological conditions, including vascular disorders, movement disorders, epilepsy, multiple sclerosis, and Alzheimer's disease.
A new study published in Brain Medicine reveals that over 26.7% of schizophrenia patients experience distinct manic symptoms, which can be predicted by the severity of positive symptoms such as hallucinations and delusions.
Dr. Kerry Ressler's research bridges the gap between molecular neuroscience and clinical psychiatry to understand PTSD's genetic architecture. Recent breakthroughs have identified over 100 significant genetic loci, representing a major step toward translating scientific discoveries into effective treatments.
Dr. Carrie Bearden's groundbreaking work combines genetic and brain development insights to identify early warning signs of psychosis in adolescents. Her research has exciting implications for personalized medicine and targeted preventive treatments.
Renowned neuroscientist Dr. Michael Meaney discusses his pioneering work on the intricate relationship between genes and environment in shaping brain health, with implications for public health policy and early intervention programs.
Neuroscientist Professor Raz Yirmiya reveals a vital link between inflammation and depression through groundbreaking research. His work suggests that both activation and suppression of the immune system can trigger depressive symptoms, highlighting the need for personalized treatment approaches.
Dr. Cathy Barr's groundbreaking research sheds light on the genetic foundations of conditions including depression, ADHD, reading disabilities, and Tourette syndrome. Her work has the potential to lead to more targeted treatments and reduce stigma around psychiatric disorders.
Emory University MD candidate Fayzan Rab's research investigates the economic and public health implications of psychedelic therapy implementation. His work emphasizes making these innovative treatments accessible to traditionally underserved communities.
Neuroscientist Inga Neumann discusses groundbreaking research on oxytocin, a neuropeptide that shapes social behavior and emotional responses. Her work has significant implications for treating social anxiety disorders and understanding stress resilience.
Researchers found that bumetanide treatment normalizes neonatal social communication in newborn pups with the fragile X mutation, but reduces post-pubertal social interaction. The study suggests stage-specific effects on social development and raises questions about timing and dosing of bumetanide for targeted interventions.
Dr. Munir Gunes Kutlu's groundbreaking research reveals specific neural mechanisms that transform sensory inputs into behavioral outputs. The discovery sheds light on the brain's dopamine system, particularly in processing information about environmental cues and rewards.
The innovative vision of Genomic Press is shaped by the story of Flicts, a tale about a color that found its true home on the moon. The publisher supports research that transcends traditional academic boundaries, providing a home for ideas that could reshape our understanding of science.
A new study published in Psychedelics found that psychedelic therapy facilitators express optimism about benefits while maintaining awareness of potential risks. The research highlights the need for robust safety protocols while maintaining optimism about therapeutic potential.
Renowned neuroscientist Dr. Peter Kalivas discusses his groundbreaking work on the tetrapartite synapse, a complex cellular structure influencing addictive behaviors. His research has revolutionized addiction treatment by identifying novel therapeutic targets beyond traditional neurotransmitter systems.
Dr. Edo Ronald de Kloet shares insights on cortisol's dual role in protecting and damaging the brain through mineralocorticoid receptors (MR) and glucocorticoid receptors (GR). His discovery has transformed our understanding of stress-related mental disorders and led to novel therapeutic pathways.
Professor Lavretsky's pioneering work integrates conventional psychiatric treatments with mind-body interventions, developing novel therapeutic combinations for treatment-resistant depression and cognitive disorders. Her research has transformed approaches to mental health and aging, emphasizing whole person health and prevention.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
Dr. Seymour Reichlin's centennial celebration highlights his ongoing scientific impact, with recent collaborations yielding new insights into hormone therapies for cognitive enhancement and emotional homeostasis. His work has established neuroendocrinology as a distinct field, bridging neuroscience, endocrinology, and clinical medicine.
Research by Prof. Falkai suggests promising new directions in schizophrenia treatment through brain plasticity and myelin regeneration. His work challenges traditional views of the disorder and opens new therapeutic possibilities, particularly when combining aerobic exercise with a repurposed drug.
A new review synthesizes evidence from molecular studies, animal research, and human trials to understand how ayahuasca influences emotional processing and memory systems. Key findings include ayahuasca's dual action through serotonin receptor types 5-HT2A and 5-HT1A.
Dr. Natalia Acosta-Baena has identified a novel genetic syndrome that reshapes our understanding of brain disorders and challenges traditional views on neurodevelopmental disorders and neurodegeneration. Her research reveals how a single gene involved in neuronal transport can influence both brain development and degeneration.
Researchers discovered a protective inherited mutation in the ADNP gene that enhances protein interactions and offers protection against developmental disorders. The study challenges previous assumptions about genetic mutations and their impact on brain development.
Dr. Philip Gold's landmark paper reveals depression's full-body impact, documenting structural brain changes and disruptions in hormone systems. His analysis highlights interconnected mechanisms underlying the disease, opening new therapeutic possibilities for innovative treatments targeting neuroendocrine dysfunction.
Dr. Etienne Sibille's work develops novel therapeutics for cognitive deficits in depression and age-related disorders through Damona Pharmaceuticals, a biopharma company he co-founded.
Professor Amal's research has uncovered crucial links between autism spectrum disorder (ASD) and Alzheimer's disease, suggesting shared molecular mechanisms that could revolutionize treatment approaches. He is developing biological diagnostics and treatments for ASD through his biotechnology companies, Point6 Bio Ltd and NeuroNOS Ltd.
A groundbreaking review finds that environmental exposure to air pollutants during prenatal development and early childhood significantly impact autism risk. The study identifies several key pathways through which air pollutants may influence ASD development, including nitrosative stress, neuroinflammation, and epigenetic modifications.
Dr. Andreazza's work focuses on identifying biomarkers for personalized treatments in metabolic psychiatry, with breakthroughs in brain organoids and mitochondrial transplantation techniques. Her innovative approach aims to revolutionize treatment for both psychiatric and metabolic disorders.
Dr. Volkow emphasizes the importance of prevention strategies and research on stress, trauma, and social determinants in substance use disorders. She also highlights promising new directions in treatment, including GLP1 medications, to address the treatment gap in addiction.
Researchers at UCSD found psilocybin therapy reduces eating disorder psychopathology and improves quality-of-life in patients with anorexia nervosa, but results vary widely among individuals. Genetic variations may influence treatment outcomes.
A groundbreaking 25-year research program has unveiled key insights into how our brains age and what factors influence cognitive performance throughout life. Childhood cognitive ability is found to be a significant predictor of intelligence test scores in older age.
Dr. Reichlin's groundbreaking work on brain-hormone interactions and his influence on generations of endocrinologists are being celebrated through a Festschrift series in Brain Medicine. The series explores multiple facets of his contributions, including pioneering work on hypothalamic control of pituitary function and early recognitio...
Dr. Andero Galí's groundbreaking research connects mouse and human fear responses, using techniques like in vivo calcium imaging in mice and human fear response studies. His approach aims to create a more comprehensive understanding of the human brain by breaking down traditional barriers between animal and human studies.
Professor Vicki Clifton's team has identified a sex-specific variant of the glucocorticoid receptor isoform that enhances inflammation in the placenta during maternal stress. This finding could transform how clinicians approach pregnancy complications and neonatal care, leading to targeted interventions based on placental function.